Subconjunctival Corticosteroid Injections for Nonnecrotizing Anterior Scleritis

Subconjunctival Triamcinolone Acetonide in the Treatment of Non-necrotizing, Non-infectious Anterior Scleritis

“…Recent retrospective studies extending over the last two decades have supported the efficacy and safety of periocular steroid injections. Early studies by Tu et al (1995) and Croasdale and Brightbill (1999) demonstrated that use of subconjunctival corticosteroid injections for treating non-necrotizing anterior scleritis could achieve rapid symptomatic relief and disease resolution with minimal systemic exposure [ 7 , 8 ]. Subsequent studies by Zamir et al (2002), Albini et al (2005), and Roufas et al (2010) confirmed the efficacy of subconjunctival triamcinolone acetonide, showing significant improvement in pain and inflammation with a favorable safety profile [ 9 - 12 ].…”

Subconjunctival Triamcinolone Acetonide in the Treatment of Non-necrotizing, Non-infectious Anterior Scleritis

“…Recent retrospective studies extending over the last two decades have supported the efficacy and safety of periocular steroid injections. Early studies by Tu et al (1995) and Croasdale and Brightbill (1999) demonstrated that use of subconjunctival corticosteroid injections for treating non-necrotizing anterior scleritis could achieve rapid symptomatic relief and disease resolution with minimal systemic exposure [ 7 , 8 ]. Subsequent studies by Zamir et al (2002), Albini et al (2005), and Roufas et al (2010) confirmed the efficacy of subconjunctival triamcinolone acetonide, showing significant improvement in pain and inflammation with a favorable safety profile [ 9 - 12 ].…”

Long-term prospective assessment of subconjunctival triamcinolone acetonide in addition to topical therapy in the management of chronic superficial keratitis

“…Subconjunctival depot injection of TA allows a slow release from the injection site, thus ensuring a prolonged duration of action which can last up to 3-6 weeks or more (9,14,15). Even if it was long believed that subconjunctival injections may have the potential to cause scleral thinning and even globe perforation (8,30), subsequent studies performed on a representative number of patients indicated the opposite (7,29). However, these studies have been conducted in human patients and there are no extensive reports on the safety of long-term subconjunctival administration in dogs, although it is a convenient and easy-to-perform therapeutic procedure in veterinary practice, as compared to certain therapeutic alternatives described above.…”

Subconjunctival Injection of Triamcinolone Acetonide in the Management of Corneal Graft Rejection and New Vessels

“…In ophthalmology, subconjunctival TA has been used for anterior scleritis, 21 , 22 pterygium surgery, 23 superior limbic keratoconjunctivitis, 24 uveitis, corneal burns and ulcers, 8 intraocular surgery, 8 , 25 and thyroid eye disease 26 . Recently, its use has been reported to successfully reverse corneal graft rejection in posterior lamellar 27 and penetrating keratoplasties 28 …”

Subconjunctival Triamcinolone Acetonide in the Treatment of Non-necrotizing, Non-infectious Anterior Scleritis

“…Recent retrospective studies extending over the last two decades have supported the efficacy and safety of periocular steroid injections. Early studies by Tu et al (1995) and Croasdale and Brightbill (1999) demonstrated that use of subconjunctival corticosteroid injections for treating non-necrotizing anterior scleritis could achieve rapid symptomatic relief and disease resolution with minimal systemic exposure [ 7 , 8 ]. Subsequent studies by Zamir et al (2002), Albini et al (2005), and Roufas et al (2010) confirmed the efficacy of subconjunctival triamcinolone acetonide, showing significant improvement in pain and inflammation with a favorable safety profile [ 9 - 12 ].…”

Long-term prospective assessment of subconjunctival triamcinolone acetonide in addition to topical therapy in the management of chronic superficial keratitis

“…Subconjunctival depot injection of TA allows a slow release from the injection site, thus ensuring a prolonged duration of action which can last up to 3-6 weeks or more (9,14,15). Even if it was long believed that subconjunctival injections may have the potential to cause scleral thinning and even globe perforation (8,30), subsequent studies performed on a representative number of patients indicated the opposite (7,29). However, these studies have been conducted in human patients and there are no extensive reports on the safety of long-term subconjunctival administration in dogs, although it is a convenient and easy-to-perform therapeutic procedure in veterinary practice, as compared to certain therapeutic alternatives described above.…”

Subconjunctival Injection of Triamcinolone Acetonide in the Management of Corneal Graft Rejection and New Vessels

“…In ophthalmology, subconjunctival TA has been used for anterior scleritis, 21 , 22 pterygium surgery, 23 superior limbic keratoconjunctivitis, 24 uveitis, corneal burns and ulcers, 8 intraocular surgery, 8 , 25 and thyroid eye disease 26 . Recently, its use has been reported to successfully reverse corneal graft rejection in posterior lamellar 27 and penetrating keratoplasties 28 …”

Subconjunctival Triamcinolone Acetonide in the Treatment of Non-necrotizing, Non-infectious Anterior Scleritis

“…Recent retrospective studies extending over the last two decades have supported the efficacy and safety of periocular steroid injections. Early studies by Tu et al (1995) and Croasdale and Brightbill (1999) demonstrated that use of subconjunctival corticosteroid injections for treating non-necrotizing anterior scleritis could achieve rapid symptomatic relief and disease resolution with minimal systemic exposure [ 7 , 8 ]. Subsequent studies by Zamir et al (2002), Albini et al (2005), and Roufas et al (2010) confirmed the efficacy of subconjunctival triamcinolone acetonide, showing significant improvement in pain and inflammation with a favorable safety profile [ 9 - 12 ].…”

Long-term prospective assessment of subconjunctival triamcinolone acetonide in addition to topical therapy in the management of chronic superficial keratitis

“…Subconjunctival depot injection of TA allows a slow release from the injection site, thus ensuring a prolonged duration of action which can last up to 3-6 weeks or more (9,14,15). Even if it was long believed that subconjunctival injections may have the potential to cause scleral thinning and even globe perforation (8,30), subsequent studies performed on a representative number of patients indicated the opposite (7,29). However, these studies have been conducted in human patients and there are no extensive reports on the safety of long-term subconjunctival administration in dogs, although it is a convenient and easy-to-perform therapeutic procedure in veterinary practice, as compared to certain therapeutic alternatives described above.…”

Subconjunctival Injection of Triamcinolone Acetonide in the Management of Corneal Graft Rejection and New Vessels

“…In ophthalmology, subconjunctival TA has been used for anterior scleritis, 21 , 22 pterygium surgery, 23 superior limbic keratoconjunctivitis, 24 uveitis, corneal burns and ulcers, 8 intraocular surgery, 8 , 25 and thyroid eye disease 26 . Recently, its use has been reported to successfully reverse corneal graft rejection in posterior lamellar 27 and penetrating keratoplasties 28 …”